A Prospective Registry Study of 68Ga-DOTATATE PET/CT Incorporation Into Treatment Planning of Intracranial Meningiomas
International Journal of Radiation Oncology*Biology*Physics · 2024
DOI: 10.1016/j.ijrobp.2023.10.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Haley K Perlow und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Ohio State University Wexner Medical Center, Columbus, Ohio. Hauptthemen laut MEDLINE: Meningioma, Organometallic Compounds, Meningeal Neoplasms, Radionuclide Imaging. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The current standard for meningioma treatment planning involves magnetic resonance imaging-based guidance. Somatostatin receptor ligands such as 68Ga-DOTATATE are being explored for meningioma treatment planning due to near-universal expression of somatostatin receptors 1 and 2 in meningioma tissue. We hypothesized that 68Ga-DOTATATE positron emission tomography (PET)-guided treatment management for patients with meningiomas is safe and effective and can identify which patients benefit most from adjuvant radiation therapy. METHODS AND MATERIALS: A single-institution prospective registry study was created for inclusion of patients with intracranial meningiomas who received a 68Ga-DOTATATE PET/CT to assist with radiation oncologist decision making. Patients who received a PET scan from January 1, 2018, to February 25, 2022, were eligible for inclusion. RESULTS: Of the 60 patients included, 40%, 47%, and 5% had World Health Organization grades 1, 2, and 3 meningiomas, respectively, and 8% (5 patients) had no grade assigned. According to Radiation Therapy Oncology Group 0539 criteria, 22%, 72%, and 7% were categorized as high, intermediate, and low risk, respectively. After completing their PET scans, 48 patients, 11 patients, and 1 patient proceeded with radiation therapy, observation, and redo craniotomy, respectively. The median follow-up for the entire cohort was 19.5 months. Of the 3 patients (5%) who experienced local failure between 9.2 and 28.5 months after diagnosis, 2 had PET-avid disease in their postoperative cavity and elected for observation before recurrence, and 1 high-risk patient with multifocal disease experienced local failure 2 years after a second radiation course and multiple previous recurrences. Notably, 5 patients did not have any local PET uptake and were observed; none of these patients experienced recurrence. Only 1 grade 3 toxicity was attributed to PET-guided radiation. CONCLUSIONS: This study examined one of the largest known populations of patients with intracranial meningiomas followed by physicians who used 68Ga-DOTATATE PET-guided therapy. Incorporating 68Ga-DOTATATE PET into future trials may assist with clinician decision making and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Ohio State University Wexner Medical Center, Columbus, Ohio.
- Ohio State University College of Medicine, Columbus, Ohio.
- Center for Biostatistics, Ohio State University, Columbus, Ohio.
- Department of Radiology, Ohio State University Wexner Medical Center, Columbus, Ohio.
- Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin.
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Zitieren
APA
Perlow, H. K., Nalin, A. P., Handley, D., Gokun, Y., Blakaj, D. M., Beyer, S. J., Thomas, E. M., Raval, R. R., Boulter, D., Kleefisch, C., Bovi, J., Chen, W. C., Braunstein, S. E., Raleigh, D. R., Knisely, J. P. S., Ivanidze, J., & Palmer, J. D. (2024). A Prospective Registry Study of 68Ga-DOTATATE PET/CT Incorporation Into Treatment Planning of Intracranial Meningiomas. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.10.014
Vancouver
Perlow HK, Nalin AP, Handley D, Gokun Y, Blakaj DM, Beyer SJ, et al. A Prospective Registry Study of 68Ga-DOTATATE PET/CT Incorporation Into Treatment Planning of Intracranial Meningiomas. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2023.10.014
BibTeX
@article{Perlow2024,
author = {Perlow, Haley K and Nalin, Ansel P and Handley, Demond and Gokun, Yevgeniya and Blakaj, Dukagjin M and Beyer, Sasha J and Thomas, Evan M and Raval, Raju R and Boulter, Daniel and Kleefisch, Christopher and Bovi, Joseph and Chen, William C and Braunstein, Steve E and Raleigh, David R and Knisely, Jonathan P S and Ivanidze, Jana and Palmer, Joshua D},
title = {A Prospective Registry Study of 68Ga-DOTATATE PET/CT Incorporation Into Treatment Planning of Intracranial Meningiomas},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
doi = {10.1016/j.ijrobp.2023.10.014}
}
EUVIMED